| FDA Widens Probe of J&J's McNeil Unit The FDA has widened its investigation into the recall of certain Johnson & Johnson children's medicines and is now inquiring into manufacturing across J&J's McNeil unit. online.wsj.com |
Designer Drugs Baffle Europe Europe is grappling with a flood of powerful and sometimes lethal new narcotics that are often legal when they first appear because authorities have never seen or banned them before. online.wsj.com |
Merck Plays Down J&J Arbitration but Risk Remains EP Vantage submits:Those bosses at Merck & Co (MRK) willing to discuss the issue right now are very much downplaying imminent arbitration with Johnson & Johnson (JNJ) over Remicade and Simponi. Understandable, perhaps, as while consensus is that Merck should win the case on technical grounds, certain other factors make this dispute not quite as cut-and-dry for Merck as it might be for J&J.As EP Vantage has previously reported, J&J has relatively little to lose over the arbitration and potentially a lot to gain (J&J ups the ante in battle for Remicade and Simponi, May 28, 2009). Merck, on the other hand, despite its protestations to the contrary, could see substantial lost value from anything other than an outright win in the dispute - even a compromise settlement could detrimentally impact Merck’s share price.Complete Story » seekingalpha.com |
Court Lets Stem-Cell Funds Flow for Now A federal appeals court said the Obama administration can continue to fund embryonic stem-cell research, reversing for the time being a trial judge's injunction barring the funding. online.wsj.com |
NeoGenomics Schedules its Q3 2010 Earnings Release for October 28, 2010 [PR Newswire] - NeoGenomics, Inc. announced today that it plans to release its third quarter 2010 financial results on Thursday, October 28, 2010. us.rd.yahoo.com |